Filing Details
- Accession Number:
- 0001181431-12-000070
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-01-03 11:44:43
- Reporting Period:
- 2011-12-06
- Filing Date:
- 2012-01-03
- Accepted Time:
- 2012-01-03 11:44:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 820096 | Perrigo Co | PRGO | Pharmaceutical Preparations (2834) | 382799573 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242215 | C Joseph Papa | C/O Perrigo Company 515 Eastern Avenue Allegan MI 49010 | President And Ceo | Yes | Yes | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2011-12-06 | 500 | $0.00 | 110,912 | No | 5 | G | Direct | |
| Common Stock | Acquisiton | 2011-12-29 | 10,000 | $17.29 | 120,912 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-12-29 | 10,000 | $99.05 | 110,912 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | G | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option Right to Buy | Disposition | 2011-12-29 | 10,000 | $0.00 | 17,042 | $17.29 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,042 | 2011-10-09 | 2016-10-09 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1sales plan adopted by the reporting person on November 29, 2011. This 10b5-1 sales plan will expire on the close of business November 20, 2012.
- The price in column 4 is a weighted average. The prices actually received ranged from $98.63 to $99.43. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
